Coronavirus disease 2019 (COVID-19) pandemic is caused by SARS-CoV-2 (SARS2, 2019-nCoV) infection, a newly emerged novel coronavirus spreading worldwide. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2(SARS2, 2019-nCoV) will be greatly important therapeutic agents for the treatment of COVID-19. The availability of therapeutic NAbs against SARS-CoV-2 will […]
Protocol Download Standard biopanning 1. S-RBD was diluted with 0.05 M PH 9.6 carbonate buffer [1]. Then add 100 μL to each well of 96-well Maxisorp plates at 4°C overnight. 2. Aspirate the solution in the well and wash each well three times with Wash Buffer [2] (300 μL/well). Complete removal of liquid at each step is essential […]
Protocol Download 1. The Capture Antibody #1 was diluted to a concentration of 1 ~ 10 ug/ml with 0.05 M PH 9.6 carbonate buffer [1]. Then add 100 μL to each well of polystyrene plate at 4℃ overnight. 2. Aspirate the solution in the well and wash each well three times with Wash Buffer [2] (300 μL/well). Complete removal of […]
SARS-CoV-2 (2019nCoV) pseudotype virus (pseudovirus, PSV) for COVID-19 related vaccines and neutralizing antibodies evaluation. The outbreak of COVID-19, caused by SARS-CoV-2 (2019-nCoV), has been a global public health threat and caught the worldwide concern. Due to its high pathogenicity and infectivity1, live SARS-CoV-2 should be handled under biosafety level 3 (BSL-3) conditions. GeneMedi has developed […]
PDF Download The ongoing worldwide severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic has a tremendous influence on public health. There is an urgent need for developing accurate detection technologies for COVID-19 pandemic. Several diagnostic strategies are available to identify or rule out current infection, identify people in need of care escalation, or to test […]
Variant of Concern 202012/01Technical briefing 2 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, month, and number. Following risk assessment with the relevant expert committee, they may […]
New and Emerging Respiratory Virus Threats Advisory Group Note of meeting Date & Location of meeting: 11:00 –13.00 18December2020 -Via telecon only In attendance: Chair: Peter Horby (PH) NERVTAG Members: Peter Openshaw (PO), Andrew Hayward (AH),Wei Shen Lim (WSL),Julian Hiscox (JHi),John Edmunds (JE), Neil Ferguson (NF), Robert Dingwall (RD),Muge Cevik (MCe), Wendy Barclay (WB), Jim McMenamin […]
New and Emerging Respiratory Virus Threats Advisory Group Note of meeting Date & Location: 12:00 –13.30 21 December 2020 -Via telecon only In attendance: Chair: Peter Horby (PH) NERVTAG Members: Andrew Hayward (AH), Julian Hiscox (JHi), John Edmunds (JE), Neil Ferguson (NF), Wendy Barclay (WB),Wei Shen Lim (WSL), Cariad Evans (CE) SPI-M: Angela McLean (AM), Graham […]
New strain of COVID-19 reported to World Health Organization. Chief Medical Officer for England, Professor Chris Whitty, said: “As announced on Monday, the UK has identified a new variant of COVID-19 through Public Health England’s genomic surveillance.” “As a result of the rapid spread of the new variant, preliminary modelling data and rapidly rising […]
Two cases of a new SARS-CoV-2 variant, which originated in South Africa, have been identified in the UK. The 2 cases were identified in the UK on 22 December 2020 and both have been in contact with someone who has travelled from South Africa. Public Health England’s Health Protection Teams have followed up with both […]
